
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Epidemiology Biomarkers & Prevention, Vol 4, Issue 6 611-616, Copyright © 1995 by American Association for Cancer Research
ARTICLES |
PH Gann, ML Daviglus, AR Dyer and J Stamler
Department of Preventive Medicine, Northwestern University Medical School, Chicago, Illinois 60611, USA.
Recent studies suggest that local levels of sympathetic nervous activity influence the growth of prostatic tissue. In several epidemiological studies, resting heart rate, an indicator of overall sympathetic activity, was positively associated with all noncardiovascular and cancer death among men. However, no previous analyses have focused on the specific relationship of heart rate to prostate cancer mortality. We studied 22,380 men enrolled in the Chicago Heart Association cohort from 1967-1973, who had heart rate (HR) determined by electrocardiogram. Mean length of follow-up (for mortality) was 19.2 years. We computed age-adjusted rates for prostate cancer death by variable of interest and fitted proportional hazards models to estimate relative risks (RRs) adjusted for potential confounders. In a model controlling for age, body mass index, blood pressure, serum cholesterol, smoking, postload plasma glucose, and years of education, the RR for a 10 beat/min higher HR was 1.26 (95% confidence interval = 1.04-1.51). Age-adjusted RRs across higher quintiles for HR were 1.00, 1.55, 1.85, 2.18, and 2.69 (P trend = 0.006). Survival curves indicated that the elevated risk was not confined to the early years of follow-up. Because little is known about factors that determine risk of prostate cancer death, these results could prove important even if due to an unmeasured etiological factor other than heart rate itself. The results are consistent with the hypothesis that local neurotrophic factors associated with sympathetic activity influence the progression of prostate cancer
This article has been cited by other articles:
![]() |
F. Bravi, L. Scotti, C. Bosetti, R. Talamini, E. Negri, M. Montella, S. Franceschi, and C. La Vecchia Self-reported history of hypercholesterolaemia and gallstones and the risk of prostate cancer Ann. Onc., June 1, 2006; 17(6): 1014 - 1017. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Otake, H. Takeda, Y. Suzuki, T. Fukui, S. Watanabe, K. Ishihama, T. Saito, H. Togashi, T. Nakamura, Y. Matsuzawa, et al. Association of Visceral Fat Accumulation and Plasma Adiponectin with Colorectal Adenoma: Evidence for Participation of Insulin Resistance Clin. Cancer Res., May 15, 2005; 11(10): 3642 - 3646. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Debes, R. O. Roberts, D. J. Jacobson, C. J. Girman, M. M. Lieber, D. J. Tindall, and S. J. Jacobsen Inverse Association between Prostate Cancer and the Use of Calcium Channel Blockers Cancer Epidemiol. Biomarkers Prev., February 1, 2004; 13(2): 255 - 259. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. MacInnis, D. R. English, D. M. Gertig, J. L. Hopper, and G. G. Giles Body Size and Composition and Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1417 - 1421. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Palatini, L. Thijs, J. A. Staessen, R. H. Fagard, C. J. Bulpitt, D. L. Clement, P. W. de Leeuw, M. Jaaskivi, G. Leonetti, C. Nachev, et al. Predictive Value of Clinic and Ambulatory Heart Rate for Mortality in Elderly Subjects With Systolic Hypertension Arch Intern Med, November 11, 2002; 162(20): 2313 - 2321. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Kristal-Boneh, H. Silber, G. Harari, and P. Froom The association of resting heart rate with cardiovascular, cancer and all-cause mortality. Eight year follow-up of 3527 male Israeli employees (the CORDIS Study) Eur. Heart J., January 2, 2000; 21(2): 116 - 124. [Abstract] [PDF] |
||||
![]() |
R. E. Schoen, C. M. Tangen, L. H. Kuller, G. L. Burke, M. Cushman, R. P. Tracy, A. Dobs, and P. J. Savage Increased Blood Glucose and Insulin, Body Size, and Incident Colorectal Cancer J Natl Cancer Inst, July 7, 1999; 91(13): 1147 - 1154. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |